Home > Publications database > Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors. > print

001     177263
005     20240229133736.0
024 7 _ |a 10.1177/03008916211056369
|2 doi
024 7 _ |a pmid:34724840
|2 pmid
024 7 _ |a 0300-8916
|2 ISSN
024 7 _ |a 2038-2529
|2 ISSN
024 7 _ |a altmetric:120812431
|2 altmetric
037 _ _ |a DKFZ-2021-02396
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Meixner, Eva
|0 0000-0001-7087-9581
|b 0
245 _ _ |a Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors.
260 _ _ |a Thousand Oaks, Calif.
|c 2023
|b Sage Publishing
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1675675003_31406
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 Feb;109(1):112-120
520 _ _ |a Vaginal cancer is a rare disease for which prospective randomized trials do not exist. We aimed to assess survival outcomes, patterns of recurrence, prognostic factors, and toxicity in the curative treatment using image-guided radiotherapy (RT).In this retrospective review, we identified 53 patients who were treated at a single center with external beam radiotherapy and brachytherapy with or without concomitant chemotherapy from 2000 to 2021.With a median follow-up of 64.5 months, the Kaplan-Meier 2-, 5-, and 7-year overall survival (OS) was found to be 74.8%, 62.8%, and 58.9%, respectively. Local and distant control were 67.8%, 65.0%, and 65.0% and 74.4%, 62.6%, and 62.6% at 2, 5, and 7 years, respectively. In univariate Cox proportional hazards ratio analysis, OS was significantly correlated to FIGO stage (hazard ratio [HR] 1.78, p = 0.042), postoperative RT (HR 0.41, p = 0.044), and concomitant chemotherapy (HR 0.31, p = 0.009). Local control rates were superior when an equivalent dose in 2-Gy fractions (EQD2) of ⩾65 Gy was delivered (HR 0.216, p = 0.028) and with the use of concurrent chemotherapy (HR 0.248, p = 0.011). Not surprisingly, local control was inferior for patients with a higher TNM stage (HR 3.303, p = 0.027). Minimal toxicity was observed with no patients having documentation of high-grade toxicity (CTCAE grade 3+).In treatment of vaginal cancer, high-dose RT in combination with brachytherapy is well tolerated and results in effective local control rates, which significantly improve with an EQD2(α/β=10) ⩾65 Gy. Multivariate analyses revealed concomitant chemotherapy was a positive prognostic factor for overall and progression-free survival.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a EQD2
|2 Other
650 _ 7 |a Squamous cell carcinoma of the vagina
|2 Other
650 _ 7 |a carbon ions
|2 Other
650 _ 7 |a high-dose-rate brachytherapy
|2 Other
650 _ 7 |a vaginal neoplasms
|2 Other
700 1 _ |a Arians, Nathalie
|b 1
700 1 _ |a Bougatf, Nina
|b 2
700 1 _ |a Hoeltgen, Line
|b 3
700 1 _ |a König, Laila
|b 4
700 1 _ |a Lang, Kristin
|0 0000-0002-5355-3173
|b 5
700 1 _ |a Domschke, Christoph
|b 6
700 1 _ |a Wallwiener, Markus
|b 7
700 1 _ |a Lischalk, Jonathan W
|b 8
700 1 _ |a Kommoss, Felix K F
|b 9
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 10
|u dkfz
700 1 _ |a Hörner-Rieber, Juliane
|b 11
773 _ _ |a 10.1177/03008916211056369
|g p. 030089162110563 -
|0 PERI:(DE-600)2267832-3
|n 1
|p 112-120
|t Tumori journal
|v 109
|y 2023
|x 2038-2529
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177263
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-08-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TUMORI J : 2022
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-26
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21